Skip to main content
. 2026 Oct 16;28(6):637–655. doi: 10.1007/s40272-026-00780-3

Table 2.

Demographics and clinical features of patients who received isavuconazole for antifungal prophylaxis

Author Country Center No. of patients Age (years, median) Underlying condition Dosage of ISA: loadinga Dosage of ISA-P: loadinga Dosage of ISA: maintenancea Dosage of ISA-P: maintenancea Route Duration Prophylaxis outcome: IFI breakthrough
Decembrino et al., 2020 [2] Italy/retrospective Multi-center 5 14.5 (3–18) HM and HCT <30 kg: 100 mg q8h × 48 h; >30 kg: adult dose 200 mg q8h × 48 h <30 kg: 100 mg/day; >30 kg 200 mg/once daily IV and oral Mean 75 days 0/5
Kunvarjee et al., 2024 [34] USA/retrospective Mono-center 20 14.8 (7–18) HM and HCT Standard Standard IV and oral Not reported

3/20

IFI: 1 proven (pathogen not available) and 2 probable/possible

Zimmerman et al., 2022 [33] France/retrospective Mono-center 6 9 (2–11) HM

f <30 kg: 100 mg ×3 for 48 h

If >30 kg: 200 mg ×3 for 48 h

<30 kg: 100 mg once daily

>30 kg: 200 mg once daily

IV and oral 90 days 0/6
Gatti et al., 2022 [36] Italy/retrospective Mono-center 6 9.5 HM 100 mg ×3/die × 24 h 100 mg once daily Not reported 174 days 0/6
Mendoza-Palomar et al., 2025 [35] Spain/retrospective Multi-center 12 11 (6–14) HM and non-hematological conditions Not reported

35 kg or less 5.4 mg/kg/day (max 200 mg)

>35 kg 200 mg/day

IV and oral Median 51 days (21–101) 0/12

HCT hematopoietic cell transplantation, HM hematologic malignancies, IFI invasive fungal infection, ISA isavuconazole, ISA-P isavuconazonium, IV intravenous, USA United States of America

aWe considered the standard dose for isavuconazonium was 10 mg/kg and for isavuconazole, 5.4 mg/kg administered three times a day for the first 48 h (loading dose) and then once daily (maintenance dose)